

Lorbrena (lorlatinib) **Prior Authorization Request Form**



LIDGENT

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

				OKOLIVI	
MEMBER INFORMATION					
LAST NAME:		FIRST NAME:			
PHONE NUMBER:		DATE OF BIRTH:			
STREET ADDRESS:					
CITY:	STATE: ZIP CODE:				
PATIENT INSURANCE ID NUMBER:					
☐ MALE ☐ FEMALE HEIG	GHT (IN/CM): WEIGI	HT (LB/KG):	ALLERG	IES:	
IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: https://magellanrx.com/member/external/commercial/common/doc/en-us/phi_disclosure_authorization.pdf					
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):					
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:					
PRESCRIBER INFORMATION					
LAST NAME:		FIRST NAME:			
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:			
NPI NUMBER:		DEA NUMBER:			
PHONE NUMBER:		FAX NUMBER:			
STREET ADDRESS:					
CITY:		STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:			
MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILI	.S:	QUANTITY:	
NEW THERAPY DURATION OF THERAPY (SPE	RENEWAL ECIFIC DATES):	IF RENEWAL: DATE THERAPY INITIATED:			

Continued on next page.





MEMBER'S LAST NAME: ______

Lorbrena (lorlatinib) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO			
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR			
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
☐ Metastatic non-small cell lung cancer	(NSCLC)	ICD-10:			
□ Other diagnosis:					
	N: PLEASE PROVIDE ALL RELEVANT CLIN	ICAL INFORMATION TO SUPPORT A			
PRIOR AUTHORIZATION.					
Clinical Information:					
Is the tumor positive for an anaplastic lymphoma kinase (ALK) rearrangement, as confirmed by an FDA approved					
test? □ Yes □ No (please submit docu	mentation)				
Has the patient tried and failed crizo	tinib? 🗆 Yes 🗆 No				
Has the patient tried and failed either alectinib OR ceritinib? ☐ Yes ☐ No					
Panawali					
Renewal:	ate a positive clinical response? Yes	□ No. (nlogse submit desumentation)			
boes patient continues to demonstr	ate a positive cliffical response: Tes	□ NO (pieuse submit documentation)			
Are there any other comments, diagn	oses, symptoms, medications tried or fa	iled, and/or any other information the			
physician feels is important to this review?					
. ,					
*Please note: Not all drugs/diagnoses are covered on all plans. This request may be denied unless all required					
information is received.		,			
ATTESTATION: I attest the information	on provided is true and accurate to the bo	est of my knowledge. I understand that			
the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical					
information necessary to verify the ac	curacy of the information reported on th	is form.			
Prescriber Signature or Electronic I.D.	Verification:	Date:			
CONFIDENTIALITY NOTICE: The documents acc	ompanying this transmission contain confidentia	health information that is legally privileged. If			
	reby notified that any disclosure, copying, distribu				
of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.					

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

© 2017–2023 by Magellan Rx Management, LLC. All Rights Reserved. Revision Date: 1/1/24 CAT0295

Page 2 of 2

